Filing Flows › ARS Pharmaceuticals (SPRY) › Q3 2026 › vs Q3 2025
ARS Pharmaceuticals (SPRY) Q3 2026 vs Q3 2025 (year over year)
ARS Pharmaceuticals's revenue rose $5.2M (+16%) from $32.5M in Q3 2025 to $37.7M in Q3 2026. The biggest changes: Product +$2.1M (+7%); Revenue Under Collaboration Agreements +$1.6M (30×); Revenue Under Supply Agreements +$1.5M (+130%).
ARS Pharmaceuticals, Q3 2026: revenue $37.7M (+16% year over year), operating margin -90.6%, net loss $35.6M, operating cash flow −$33.7M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Product | $33.4M | $31.3M | $2.1M | +7% |
| Revenue Under Supply Agreements | $2.6M | $1.1M | $1.5M | +130% |
| Revenue Under Collaboration Agreements | $1.7M | $55K | $1.6M | 30× |
| Revenue | $37.7M | $32.5M | $5.2M | +16% |
| Net loss | $35.6M | $51.2M | −$15.6M | -30% |
| Costs & expenses | $73.3M | $85.7M | −$12.4M | -14% |
| Operating costs | $71.9M | $85.7M | −$13.8M | -16% |
| Interest & other, net | $1.4M | −$2.0M | $3.5M | — |
| Research & development | $18.3M | $2.8M | $15.5M | +564% |
| SG&A | $43.5M | $74.8M | −$31.2M | -42% |
| Other operating costs | $10.1M | $8.2M | $1.9M | +23% |
| Operating cash sources | $42.2M | $53.1M | −$10.9M | -20% |
| Depreciation & amortization | $415K | $391K | $24K | +6% |
| Share-based compensation | $8.1M | $5.7M | $2.4M | +43% |
| Cash used in operations | $33.7M | $47.0M | −$13.3M | -28% |
| Net loss absorbed | $35.6M | $51.2M | −$15.6M | -30% |
| Working capital & other | $6.7M | $2.0M | $4.7M | +237% |
Questions
How much did ARS Pharmaceuticals's revenue grow year over year in Q3 2026?
ARS Pharmaceuticals's revenue rose $5.2M (+16%) from $32.5M in Q3 2025 to $37.7M in Q3 2026.
What drove ARS Pharmaceuticals's revenue change in Q3 2026?
Product +$2.1M (+7%); Revenue Under Collaboration Agreements +$1.6M (30×); Revenue Under Supply Agreements +$1.5M (+130%).